A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.
The impurity N-Nitrosodiethylamine (NDEA) was detected in quantities above the acceptable limit in certain tablets containing valsartan, the FDA said.
The announcement comes a month after Mylan NV said it will recall all lots of its blood pressure medicines containing valsartan, an angiotensin II receptor blocker, after global health authorities clamped down on the drug.
No drugs in Canadian market are affected by the Aurobindo Pharma recall, a Health Canada spokesperson told Global News.
WATCH BELOW: Several blood pressure medications recalled in 2018
The FDA said it will continue to investigate and test all angiotensin II receptor blockers for the presence of NDEA and another probable carcinogen N-nitrosodimethylamine.In October last year, the FDA halted imports of drug ingredients or medicines containing ingredients produced at a factory of a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals.
© 2019 Reuters
Trending
-
Superyacht sinking: Manslaughter charges considered as last body found9136 Read
-
‘Dangerous precedent’: Union reacts to board ordering rail employees back to work6489 Read
-
Taliban bans women’s voices, bare faces from public in new restrictive laws4705 Read
-
1st lung cancer vaccine trials launch, powered by COVID mRNA technology3365 Read
-
Liberals face storm clouds as cabinet meets in Halifax2251 Read
-
Stranded Boeing astronauts to return in 2025 on competitor SpaceX: NASA2147 Read
You are viewing an Accelerated Mobile Webpage.
View Original Article